For comments, suggestions
Created with Raphaël 2.1.0 05.06.1995 Opening of the national phase 30.06.1998 Publication of the PCT application (A) 31.12.1999 Publication of the decision of grant (B2) 20.06.2000 Preliminary and substantive examination 30.06.2000 Completion of the opposition filing period 30.11.2000 Issuance of patent (C2) 31.01.2014 Publication of expiration of the patent

Patent expired


(11)Number of the document1367
(21)Number of the application95-0311
(22)Filing date of the application1993.11.12
 Date of filing the request for examination (de fond) 30.08.1995
(71)Name(s) of applicant(s), code of the countryIDEC PHARMACEUTICALS CORPORATION, US;
(72)Name(s) of inventor(s), code of the countryANDERSON, Darrell, R., US; RASTETTER, William, H., US; HANNA, Nabil, US; LEONARD, John, E., US; NEWMAN, Roland, A., US; REFF, Mitchell, E., US;
(73)Name(s) of owner(s), code of the countryBiogen Idec Inc., US;
(54)Title of the invention Methods of B-cells lymphoma treatment, anti-CD20 antibodies, hybridoma
(13)Kind-of-document code C2
(51)International Patent Classification A61K 38/00 (2006.01); A61K 47/48 (2006.01); C07K 16/28 (2006.01);
(19)CountryUS
(41)Date of publication of the application1998.06.30
(45)Date of publication of patent granting decision:1999.12.31
(47)Date of issuance of patent2000.12.31
(30)Priority07/978,891, 1992.11.13, US; 08/149,099, 1993.11.03, US
(74)Patent attorneySKIDAN Natalia, Str. Andrei Doga 2/1, MD-2024, Chişinau, Republica Moldova
 Substantive examiner(s)TIMONIN Alexandru
(85)Date of introducing the national procedure1995.06.05
(86)International applicationPCT/US1993/010953, 1993.11.12
(87)International publicationWO 1994/11026, 1994.05.26
 Expired patents; Date of expiration2014.01.31
 Payment for maintenance up to the date2013.11.12
 Change of the owner
Nr. şi data deciziei:8059, 2013.07.02
Datele iniţiale:IDEC PHARMACEUTICALS CORPORATION, US
Datele finale:Biogen Idec Inc., US
Up
/inventions/Details.aspx?id=95-0311